PCM
LLY icon

Prelude Capital Management’s Eli Lilly LLY Stock Holding History

Prelude Capital Management’s Portfolio LLY Stock Details LLY Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q1 		$2.6M Sell
2,830
-1,770
-38% -$1.79M 0.2% 122
2025
Q4 		$4.94M Buy
4,600
+1,270
+38% +$1.21M 0.36% 44
2025
Q3 		$2.54M Buy
3,330
+1,526
+85% +$1.14M 0.2% 109
2025
Q2 		$1.41M Sell
1,804
-702
-28% -$546K 0.14% 187
2025
Q1 		$2.07M Sell
2,506
-840
-25% -$699K 0.16% 145
2024
Q4 		$2.58M Sell
3,346
-866
-21% -$717K 0.16% 130
2024
Q3 		$3.73M Sell
4,212
-3,415
-45% -$3.07M 0.23% 105
2024
Q2 		$6.91M Hold
7,627
– – 0.48% 32
2024
Q1 		$5.93M Buy
7,627
+2,023
+36% +$1.44M 0.31% 46
2023
Q4 		$3.27M Sell
5,604
-784
-12% -$458K 0.22% 95
2023
Q3 		$3.43M Sell
6,388
-940
-13% -$484K 0.22% 97
2023
Q2 		$3.44M Buy
7,328
+4,428
+153% +$1.86M 0.22% 90
2023
Q1 		$996K Sell
2,900
-577
-17% -$195K 0.06% 321
2022
Q4 		$1.27M Sell
3,477
-132
-4% -$46.8K 0.07% 308
2022
Q3 		$1.17M Sell
3,609
-3,568
-50% -$1.13M 0.04% 380
2022
Q2 		$2.33M Buy
7,177
+4,611
+180% +$1.38M 0.07% 250
2022
Q1 		$735K Sell
2,566
-4,121
-62% -$1.06M 0.02% 701
2021
Q4 		$1.85M Buy
6,687
+3,088
+86% +$783K 0.05% 347
2021
Q3 		$832K Sell
3,599
-1,849
-34% -$456K 0.02% 647
2021
Q2 		$1.25M Buy
+5,448
New +$1.09M 0.04% 495
2020
Q4 		– Sell
-671
Closed -$99K – 1670
2020
Q3 		$99K Buy
+671
New +$104K ﹤0.01% 914
2020
Q2 		– Sell
-940
Closed -$130K – 2128
2020
Q1 		$130K Sell
940
-10,609
-92% -$1.46M 0.01% 535
2019
Q4 		$1.52M Buy
+11,549
New +$1.34M 0.06% 274
2019
Q2 		– Sell
-468
Closed -$61K – 1926
2019
Q1 		$61K Sell
468
-2,861
-86% -$348K ﹤0.01% 1071
2018
Q4 		$385K Buy
+3,329
New +$372K 0.03% 539
2017
Q3 		– Sell
-2,415
Closed -$199K – 1783
2017
Q2 		$199K Sell
2,415
-31,374
-93% -$2.56M 0.02% 580
2017
Q1 		$2.84M Buy
33,789
+710
+2% +$56.9K 0.27% 82
2016
Q4 		$2.43M Buy
33,079
+9,566
+41% +$712K 0.29% 90
2016
Q3 		$1.89M Buy
23,513
+19,208
+446% +$1.54M 0.2% 106
2016
Q2 		$339K Sell
4,305
-787
-15% -$59.2K 0.05% 361
2016
Q1 		$367K Buy
5,092
+4,081
+404% +$309K 0.05% 360
2015
Q4 		$85K Buy
+1,011
New +$83.9K 0.01% 868
2015
Q2 		– Sell
-2,213
Closed -$161K – 1883
2015
Q1 		$161K Buy
2,213
+1,753
+381% +$125K 0.02% 744
2014
Q4 		$32K Sell
460
-636
-58% -$42.9K ﹤0.01% 1602
2014
Q3 		$71K Buy
1,096
+319
+41% +$20.2K 0.01% 1250
2014
Q2 		$48K Sell
777
-1,365
-64% -$81.4K 0.01% 1368
2014
Q1 		$126K Sell
2,142
-788
-27% -$44K 0.02% 928
2013
Q4 		$149K Sell
2,930
-2,141
-42% -$107K 0.02% 698
2013
Q3 		$255K Buy
5,071
+1,971
+64% +$103K 0.04% 468
2013
Q2 		$152K Buy
+3,100
New +$169K 0.03% 499

Other funds holding LLY

Lilly Endowment
Lilly Endowment Indiananapolis, Indiana $108B AUM 53.87% 1-Year Est. Return
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
VCM
Vanguard Capital Management Malvern, Pennsylvania $4.04T AUM
PNC Financial Services Group
PNC Financial Services Group Pittsburgh, Pennsylvania $173B AUM 20.72% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return
Fidelity Investments
Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return
Capital Research Global Investors
Capital Research Global Investors Los Angeles, California $645B AUM 30.41% 1-Year Est. Return
VPM
Vanguard Portfolio Management Malvern, Pennsylvania $1.91T AUM
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.61T AUM 30.72% 1-Year Est. Return
Capital World Investors
Capital World Investors Los Angeles, California $733B AUM 35.63% 1-Year Est. Return

Prelude Capital Management's LLY Position: Q1 2026 in Review

Prelude Capital Management reduced its Eli Lilly (LLY) stake by 38% in Q1 2026, selling an estimated $1.79M and leaving 2,830 shares worth $2.6M. The position accounts for 0.2% of the portfolio, ranked #122.

Prelude Capital Management first reported a position in LLY in Q2 2013 and has held it in 40 quarters since. The position peaked at $6.91M in Q2 2024. 4,355 funds tracked by Wall St. Rank hold LLY as of Q1 2026.

  • Prelude Capital Management held 2,830 shares of Eli Lilly worth $2.6M as of Q1 2026.
  • Prelude Capital Management sold 1,770 Eli Lilly shares in Q1 2026, an estimated $1.79M.
  • Eli Lilly made up 0.2% of Prelude Capital Management's portfolio in Q1 2026, its #122 holding.
  • Prelude Capital Management first reported a position in Eli Lilly in Q2 2013 and has held it in 40 quarters since.
  • Prelude Capital Management's Eli Lilly position peaked at $6.91M in Q2 2024.
  • 4,355 funds tracked by Wall St. Rank held Eli Lilly as of Q1 2026.

Based on Prelude Capital Management's 13F filing for Q1 2026, filed 15 May 2026.